BOSTON and NEWTON, Mass. — Foundation Medicine, Inc., a precision medicine company transforming lives in cancer care and beyond, announced a partnership with Manifold, an artificial intelligence data platform for life sciences, to bring advanced AI capabilities to FoundationInsights, the company’s cloud-based data analytics and visualization platform.
The enhanced version of FoundationInsights is now available for biopharmaceutical partners and offers greater flexibility for answering key questions throughout the drug development process. By integrating Manifold’s AI technology, the platform provides a faster and more intuitive way to derive insights from Foundation Medicine’s proprietary dataset of de-identified genomic results from more than 800,000 patients.
FoundationInsights allows users to rapidly identify patient groups or explore the prevalence of specific genomic alterations. With new AI-enabled natural language search functions, researchers can easily set complex genomic criteria. Technical users can also perform customized, in-depth analyses using programming languages such as Python and R, enabling deeper exploration of genomic data.
“Foundation Medicine is using AI and machine learning to power our real-world data solutions to accelerate drug discovery and development,” said Troy Schurr, chief biopharma business officer at Foundation Medicine. “With new AI-powered capabilities from Manifold, biopharmaceutical partners can find the answers needed to make decisions faster than ever before. Our partners now have a one-stop shop to easily access comprehensive multimodal data combined with advanced analytics and visualization tools, so patients can benefit from advances in precision medicine.”
“Foundation Medicine is a pioneer in precision diagnostics,” said Vinay Seth Mohta, chief executive officer and co-founder of Manifold. “By combining Foundation Medicine’s powerful multimodal databases with Manifold’s purpose-built AI capabilities for life sciences, we can make it easier for researchers to work smarter and faster to unlock the answers needed to discover innovative personalized therapies.”
